Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
- 12 January 2021
- journal article
- letter
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (3), e45-e47
- https://doi.org/10.2337/dc20-2265
Abstract
No abstract availableFunding Information
- Merck Sharp & Dohme
- Pfizer
This publication has 5 references indexed in Scilit:
- Dapagliflozin in Patients with Chronic Kidney DiseaseThe New England Journal of Medicine, 2020
- Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesThe New England Journal of Medicine, 2020
- How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialDiabetes Care, 2017
- Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized StudyDiabetes Therapy, 2017
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes MellitusCirculation, 2016